Literature: Radioimmunotherapy
Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, Goldenberg DM.
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Haematologica. 2014 Aug 22.
Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, Abe Y, Hayashi T, Sawamoto H, Kaneko K, Shimokawa M, Nakagawa M.
Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era.
Int J Hematol. 2014 Aug 21.
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY.
Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen.
Biol Blood Marrow Transplant. 2014 Jul 29.
Repetto-Llamazares AH, Larsen RH, Giusti AM, Riccardi E, Bruland OS, Selbo PK, Dahle J.
177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice.
PLoS One. 2014 Jul 28;9(7):e103070.
Vaidyanathan G, Zalutsky MR.
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
Curr Radiopharm. 2011 Oct;4(4):283-94.
Barbet J, Chatal JF.
The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):271-3.
Buchmann I, Meyer RG, Mier W, Haberkorn U.
Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):484-98.
Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD.
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
J Nucl Med. 2008 Jan;49(1):30-8.
Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD.
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
Nucl Med Biol. 2007 Oct;34(7):779-85.